98 related articles for article (PubMed ID: 34166727)
1. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
Jannu AK; Puppala ER; Gawali B; Syamprasad NP; Alexander A; Marepally S; Chella N; Gangasani JK; Naidu VGM
Int J Pharm; 2021 Aug; 605():120819. PubMed ID: 34166727
[TBL] [Abstract][Full Text] [Related]
2. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
[TBL] [Abstract][Full Text] [Related]
3. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP
J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
5. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
6. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties.
Incerti M; Russo S; Corrado M; Giorgio C; Ballabeni V; Chiodelli P; Rusnati M; Scalvini L; Callegari D; Castelli R; Vacondio F; Ferlenghi F; Tognolini M; Lodola A
Eur J Med Chem; 2020 Mar; 189():112083. PubMed ID: 32000051
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
8. Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.
Jehle J; Staudacher I; Wiedmann F; Schweizer P; Becker R; Katus H; Thomas D
Br J Pharmacol; 2012 Dec; 167(7):1563-72. PubMed ID: 22845314
[TBL] [Abstract][Full Text] [Related]
9. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
10. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.
Posthumadeboer J; Piersma SR; Pham TV; van Egmond PW; Knol JC; Cleton-Jansen AM; van Geer MA; van Beusechem VW; Kaspers GJ; van Royen BJ; Jiménez CR; Helder MN
Br J Cancer; 2013 Oct; 109(8):2142-54. PubMed ID: 24064975
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.
Wang S; Placzek WJ; Stebbins JL; Mitra S; Noberini R; Koolpe M; Zhang Z; Dahl R; Pasquale EB; Pellecchia M
J Med Chem; 2012 Mar; 55(5):2427-36. PubMed ID: 22329578
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Bhattacharyya J; Ren XR; Mook RA; Wang J; Spasojevic I; Premont RT; Li X; Chilkoti A; Chen W
Nanoscale; 2017 Aug; 9(34):12709-12717. PubMed ID: 28828438
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
15. Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo.
Andrade F; Rafael D; Vilar-Hernández M; Montero S; Martínez-Trucharte F; Seras-Franzoso J; Díaz-Riascos ZV; Boullosa A; García-Aranda N; Cámara-Sánchez P; Arango D; Nestor M; Abasolo I; Sarmento B; Schwartz S
J Control Release; 2021 Mar; 331():198-212. PubMed ID: 33482272
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and metabonomics of niclosamide micelles.
Hang J; Chen Y; Liu L; Chen L; Fang J; Wang F; Wang M
J Cell Mol Med; 2022 Sep; 26(18):4814-4824. PubMed ID: 35923077
[TBL] [Abstract][Full Text] [Related]
18. Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells.
Russo A; Pellosi DS; Pagliara V; Milone MR; Pucci B; Caetano W; Hioka N; Budillon A; Ungaro F; Russo G; Quaglia F
Int J Pharm; 2016 Sep; 511(1):127-139. PubMed ID: 27374195
[TBL] [Abstract][Full Text] [Related]
19. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
20. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
